Executive Brief

News Report

The News: WHO updates guidelines for severe asthma management in 2026.
Clinical Win: New criteria for triple inhaler therapy to enhance patient outcomes.
Target Specialty: Pulmonology

Key Data at a Glance

Global asthma prevalence: 363 million people affected
Severe asthma percentage: 5-10% of asthma patients

In 2026, the World Health Organization (WHO) released updated guidelines for the management of severe asthma, emphasizing the role of triple inhaler therapy. This update is crucial for healthcare providers as it outlines patient selection criteria for Trimbow, Trelegy, and Breztri, aiming to enhance asthma control and reduce exacerbations in patients with severe asthma.

Clinical Context

Asthma is a chronic inflammatory disease affecting millions worldwide, with an estimated 363 million people impacted in 2023 [1]. It is characterized by airway inflammation, leading to symptoms such as wheezing, coughing, and shortness of breath. Severe asthma, which affects about 5-10% of asthma patients, often does not respond adequately to standard treatments, necessitating advanced therapeutic options. Triple inhaler therapy, which combines a corticosteroid, a long-acting beta-agonist, and a long-acting muscarinic antagonist, has emerged as a promising approach to improve asthma control and reduce the frequency of exacerbations. The updated guidelines provide a structured framework for clinicians to identify patients who would benefit most from these therapies, particularly in settings where asthma management is often inadequate [2].

Key Findings

The 2026 WHO guidelines recommend the use of triple therapy with Trimbow, Trelegy, or Breztri for patients with severe asthma who remain uncontrolled on dual therapy with inhaled corticosteroids and long-acting beta-agonists.

Patient selection criteria include a history of frequent exacerbations, persistent symptoms despite optimal use of dual therapy, and a demonstrated inability to achieve control with existing medications [2].

The guidelines emphasize the importance of regular follow-up and monitoring to assess treatment effectiveness and adjust therapy as needed to ensure optimal asthma management [1].

The use of these inhalers has been shown to improve lung function and reduce the risk of severe exacerbations, which is critical for enhancing the quality of life in patients with severe asthma.

What This Means for Clinical Practice

The updated WHO guidelines on asthma management underscore the need for healthcare providers to carefully assess patients with severe asthma for appropriate therapy. Clinicians should consider initiating triple inhaler therapy in patients who exhibit poor control on dual therapy, particularly those with a history of exacerbations and persistent symptoms. This structured approach not only aims to improve patient outcomes but also enhances the overall management of asthma in clinical practice. As asthma remains a leading cause of morbidity, understanding the specific criteria for step-up therapy will enable clinicians to make informed decisions that align with the latest evidence-based practices. How will these guidelines influence your current treatment protocols for severe asthma?

Clinical Perspective

Workflow: Clinicians should implement the new guidelines to assess and manage patients with severe asthma more effectively.

Economics: Improved management may reduce healthcare costs associated with asthma exacerbations and hospitalizations.

Patient Outcomes: Enhanced control of severe asthma symptoms can lead to better quality of life for patients.

Dr. Nikhil Chatterjee, Pulmonology

Asthma Triple Inhaler Therapy: 2026 Guidelines on Trimbow, Trelegy, and Breztri for Severe Asthma Management

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Pulmonology in your inbox.

Related Drug Updates

WHO Releases 2026 Smoking Cessation Guidelines: Cytisinicline vs Varenicline vs NRT vs Bupropion

Trimbow vs Trelegy: New Guidelines for Severe Asthma Management

Biologics for Severe Asthma: Comparing Mepolizumab, Benralizumab, Dupilumab, Tezepelumab, and Depemokimab

Verified HCP Portal